ImmunoGen’s stock is up 12% after the FDA accepts application for new ovarian-cancer therapy


Shares of ImmunoGen Inc. IMGN, +1.42% jumped 12.0% in premarket trading on Monday after the company said the Food and Drug Administration accepted an application for its experimental ovarian-cancer treatment. The mirvetuximab soravtansine monotherapy has a Prescription Drug User Fee Act action date of Nov. 28. ImmuoGen said it is still enrolling patients in a confirmatory trial, with plans to announce data from that study early next year. The company’s stock has declined 51.7% this year, while the broader S&P 500 SPX, +0.01% is down 18.1%.

This article was originally published by Read the original article here.

Previous article: Inheriting a house? Read this before you make any rash decisions
Next article: Millennial homeowners prefer to do renovations, which could be favorable for Home Depot and Lowe’s


Please enter your comment!
Please enter your name here